Cinclus Pharma appoints PSI as CRO for its eGERD phase III program
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cinclus Pharma (“the Company”) announced today that Swiss-based global company PSI CRO will serve as the clinical research organization (CRO) for the phase III program of the Company’s lead drug candidate, linaprazan glurate, for the treatment of erosive gastroesophageal reflux disease (eGERD).
The program will involve approximately 500 patients at nearly 100 sites across Europe and the USA. Recruitment of the first patient is planned for 2025, with the first readout of healing data expected in 2026.
Linaprazan glurate is a new drug developed to provide effective, fast, and long-lasting symptom relief in patients with erosive gastroesophageal reflux disease. It has shown superior results to standard-of-care in previous clinical studies and is expected to offer an improved treatment option for patients suffering from this chronic disease.
"We are very pleased to initiate this strategic partnership with PSI,” said Christer Ahlberg, CEO of Cinclus Pharma. “After a comprehensive evaluation process involving more than ten different CROs, it became clear that PSI has the experience and expertise needed to conduct our phase III program for eGERD successfully. Their global presence, experience in the GI field, and strong track record, not least in timely delivery, make them the optimum partner. We look forward to taking the next step in the development of linaprazan glurate together with PSI to be able to offer a new and effective treatment for patients with severe erosive GERD."
“Gastrointestinal disease is a key focus for PSI, a passion we share with the pioneers in GERD treatment at Cinclus Pharma and our global network of over 4,000 experienced GI sites,” said Kasia Moscicka, Head of Feasibility at PSI. “We are proud to leverage this dedication to help advance Cinclus Pharma’s clinical program and bring hope to patients affected by erosive GERD worldwide.”
About PSI
PSI is a privately-owned, full-service clinical research organization (CRO) operating globally. PSI’s global reach supports clinical trials across multiple countries and continents and specializes in the planning and execution of global pivotal registration clinical trials. With an exceptionally high repeat and referral business rate combined with minimal staff turnover, PSI is committed to being the best CRO in the world as measured by its employees, customers, investigators, and vendors. Global headquarters are located in Switzerland at 113a Baarerstrasse, Zug 6300. www.psi-cro.com.